Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial
Year: 2018
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet Haematology
Authors: Uday R Popat, Rohtesh S Mehta, Roland Bassett, Julianne Chen, Benigno C Valdez, Jitesh Kawedia, Sairah Ahmed, Amin M Alousi, Paolo Anderlini, Geath Al-Atrash, Qaiser Bashir, Stefan O Ciurea, Chitra M Hosing, Jin S Im, Roy Jones, Partow Kebriaei, Issa Khouri, David Marin, Yago Nieto, Amanda Olson, Betul Oran, Simrit Parmar, Katayoun Rezvani, Muzaffar H Qazilbash, Nina Shah, Samer A Srour, Elizabeth J Shpall, Richard E Champlin, Borje S Andersson
Institution: The University of Texas MD Anderson Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Award: Cancer Center Support Grant
OpenAlex ID: W2899427992